Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic Carcinoma

NCT02195180 is registered in ClinicalTrials.gov with ERYtech Pharma as lead sponsor.

NCT NCT02195180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02195180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic Carcinoma
Lead sponsor
ERYtech Pharma
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2014
Completion date
November 30, 2017
Enrollment
141 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma metastatic